ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Anti-cancer effects of carvacrol on NUF2, CASP3 and CLDN6 expression in T47D breast cancer cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carvacrol induces apoptosis, modulates oxidative stress, and promotes G0/G1 cell cycle arrest in colorectal cancer cells.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) remains a major global health challenge, with rising incidence and mortality despite advances in diagnosis and treatment. Identifying new therapeutic agents targeting key molecular pathways is critical for improving patient outcomes. This study investigated the anticancer potential of carvacrol, a natural monoterpenoid phenol, in T47D luminal A BC cells, focusing on its effects on cell viability, migration, oxidative stress, and the expression of NUF2, CASP3 and CLDN6. T47D cells were treated with 480 µM carvacrol for 48 h. Cell viability, wound healing assay, intracellular reactive oxygen species (ROS) levels assay and gene expression were evaluated. Carvacrol significantly inhibited cell viability and reduced wound closure compared with controls. It markedly decreased intracellular ROS levels, indicating modulation of cellular redox status. Gene expression analysis revealed a significant downregulation of NUF2 (P < 0.01) and upregulation of both CASP3 (P < 0.01) and CLDN6 (P < 0.001). These findings suggest that carvacrol treatment is associated with transcriptional changes in genes related to proliferation, apoptosis, and cell junction dynamics. Carvacrol exhibits anticancer-related effects in T47D luminal A BC cells by altering cell viability, migration, oxidative stress, and the expression of NUF2, CASP3, and CLDN6. While these results highlight carvacrol's multi-targeted transcriptional impact, further studies are required to clarify the underlying molecular mechanisms and functional consequences.
Indexed as
Identifiers
41569314What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.